Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance.


Journal

Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857

Informations de publication

Date de publication:
10 2022
Historique:
revised: 06 07 2022
received: 18 02 2022
accepted: 12 07 2022
pubmed: 16 7 2022
medline: 1 9 2022
entrez: 15 7 2022
Statut: ppublish

Résumé

Hepatorenal syndrome-acute kidney injury (HRS-AKI) is a serious complication of severe liver disease with a clinically poor prognosis. Supportive care using vasoconstrictors and intravenous albumin are the current mainstays of therapy. Terlipressin is an efficacious vasoconstrictor that has been used for 2 decades as the first-line treatment for HRS-AKI in Europe and has demonstrated greater efficacy in improving renal function compared to placebo and other vasoconstrictors. One of the challenges associated with terlipressin use is monitoring and mitigating serious adverse events, specifically adverse respiratory events, which were noted in a subset of patients in the recently published CONFIRM trial, the largest randomized trial examining terlipressin use for HRS-AKI. In this article, we review terlipressin's pharmacology, hypothesize how its mechanism contributes to the risk of respiratory compromise and propose strategies that will decrease the frequency of these events by rationally selecting patients at lower risk for these events.

Identifiants

pubmed: 35838488
doi: 10.1111/liv.15367
pmc: PMC9762017
mid: NIHMS1853854
doi:

Substances chimiques

Albumins 0
Vasoconstrictor Agents 0
Lypressin 50-57-7
Terlipressin 7Z5X49W53P

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2124-2130

Subventions

Organisme : NIDDK NIH HHS
ID : K23 DK128567
Pays : United States

Informations de copyright

© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Hepatology. 2021 Aug;74(2):1014-1048
pubmed: 33942342
Am J Kidney Dis. 2020 Nov;76(5):710-719
pubmed: 32622560
Hepatology. 2002 May;35(5):1179-85
pubmed: 11981768
Aliment Pharmacol Ther. 2020 Jul;52(2):351-358
pubmed: 32495956
Eur J Gastroenterol Hepatol. 2010 Sep;22(9):1085-92
pubmed: 20453655
Cochrane Database Syst Rev. 2017 Jun 14;6:CD005162
pubmed: 29943803
Gastroenterology. 2016 Jun;150(7):1579-1589.e2
pubmed: 26896734
Gastroenterology. 2008 May;134(5):1360-8
pubmed: 18471513
Hepatology. 2002 Oct;36(4 Pt 1):941-8
pubmed: 12297842
N Engl J Med. 2021 Oct 21;385(17):1593-1602
pubmed: 34670045
Eur Heart J Acute Cardiovasc Care. 2012 Dec;1(4):275-80
pubmed: 24062917
PLoS One. 2014 Sep 09;9(9):e107466
pubmed: 25203311
Clin Gastroenterol Hepatol. 2018 Nov;16(11):1792-1800.e3
pubmed: 29391267
N Engl J Med. 2021 Mar 4;384(9):808-817
pubmed: 33657293
J Hepatol. 2018 Aug;69(2):406-460
pubmed: 29653741
N Engl J Med. 2004 Jul 22;351(4):327-36
pubmed: 15269312
Hepatology. 1992 May;15(5):809-15
pubmed: 1568722
Crit Care Med. 2009 Mar;37(3):876-81
pubmed: 19237891
Curr Gastroenterol Rep. 2020 Jul 10;22(9):45
pubmed: 32651721
Hepatology. 2020 Feb;71(2):600-610
pubmed: 30076614
J Physiol. 2004 Jun 15;557(Pt 3):704
pubmed: 15131237
Nat Rev Nephrol. 2020 Mar;16(3):137-155
pubmed: 31723234
Hepatology. 2013 Apr;57(4):1651-3
pubmed: 23463403
Nephrol Dial Transplant. 2020 Sep 1;35(9):1554-1561
pubmed: 30887050
Gastroenterology. 2011 Feb;140(2):488-496.e4
pubmed: 20682324
Cochrane Database Syst Rev. 2019 Sep 12;9:CD013103
pubmed: 31513287
J Hepatol. 2015 Apr;62(4):968-74
pubmed: 25638527
Hepatology. 2015 Aug;62(2):567-74
pubmed: 25644760
J Exp Pharmacol. 2017 Dec 20;10:1-7
pubmed: 29302194
Gut. 2007 Sep;56(9):1310-8
pubmed: 17389705
Aliment Pharmacol Ther. 2017 Jun;45(11):1390-1402
pubmed: 28370090
N Engl J Med. 2021 Mar 4;384(9):818-828
pubmed: 33657294
Hepatology. 2016 Mar;63(3):983-92
pubmed: 26659927
Liver Transpl. 2022 Mar;28(3):466-482
pubmed: 34714972
Gastroenterology. 1991 Oct;101(4):1060-7
pubmed: 1832407
JAMA. 2013 Aug 14;310(6):591-608
pubmed: 23842577

Auteurs

Andrew S Allegretti (AS)

Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

Ram M Subramanian (RM)

Divisions of Gastroenterology and Hepatology and Pulmonary and Critical Care Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.

Claire Francoz (C)

Hepatology and Liver Intensive Care Unit, Hospital Beaujon, Clichy, France.

Jody C Olson (JC)

Divisions of Gastroenterology, Hepatology, Pulmonary and Critical Care Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.

Andrés Cárdenas (A)

GI and Liver Unit, Institut de Malalties Digestives, Hospital Clínic, Barcelona, Spain. Institut d'Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS), Barcelona and Ciber de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH